D
espite recent increases in therapeutic options, lung cancer remains one of the leading causes of cancer death. 1 This malignancy is often resistant to chemotherapy and frequently presents metastasis to distant organs in the early phase of the disease. Even if the primary tumor is removed surgically, relapse at the primary or distant sites frequently occurs. To overcome these problems, new therapeutic approaches including cancer immunogene therapy have recently been investigated. 2 Several reports have identified tumor-specific antigens for some tumors, and tumor-specific cytotoxic T cells (CTLs ) have been successfully isolated from patients with cancer. 3 However, most malignant tumors, including lung cancer, evade host immune surveillance. 4 It has also been suggested that antigen-specific T cells may be rendered tolerant early in the course of tumor progression. 5 Recent studies have revealed that the state of activation and /or maturation of antigen-presenting cells ( APCs ) may determine whether T cells are primed or rendered tolerant. 6 CD40 is a member of the tumor necrosis factor ( TNF ) receptor family of cell surface proteins expressed on B cells, macrophages, and dendritic cells. It binds a CD40 ligand (CD40L /CD154 ), which is a member of the TNF superfamily expressed on activated T cells, basophils, and mast cells. 7 Although the CD40 ± CD40L interaction is primarily implicated in the establishment of humoral immunity, 8 recent reports demonstrated that the CD40 ±CD40L interaction also plays a critical role in the induction of antitumor immunity, 9 especially for the priming of tumor-specific T cells. 10 We previously reported that alveolar macrophages were activated by stimulation through CD40 ± CD40L interaction and developed tumoricidal activity against lung cancer cells, and that interferon ( IFN )-induced a high expression of CD40 molecule on the surface of alveolar macrophages. 11 Considering these findings, we hypothesized that CD40L gene transduction into lung cancer cells could activate APCs surrounding the tumor tissue, and induce antitumor immunity against parental lung cancer cells in vivo, although lung cancer cells generally reveal low antigenicity, and it seems to be difficult to induce lung cancer ±specific cellular immunity, unlike in melanoma cells. In the present study, we studied the effect of CD40L gene transduction combined with IFN -gene transduction into lung cancer cells for the efficient induction of antitumor immunity against lung cancer. C57BL /6 mice (H -2 b ) were purchased from SLC ( Shizuoka, Japan ). CD40 -deficient mice were generated by a gene -targeting technique previously reported. 8 A CD40 + / À mouse was produced by backcrossing the originally described CD40 À / À mouse to a C57BL /6 mouse. The heterozygous littermates were intercrossed to generate the CD40 À / À mice used in this study. These mice were genotyped by a polymerase chain reaction (PCR ) of genomic DNA obtained from a tail biopsy using primers to identify the rearranged CD40 locus, as described previously. 8 All these mice were maintained at the Institute for Laboratory Animal Research of the Nagoya University School of Medicine.
MATERIALS AND METHODS

Mice
Tumor cells
A murine lung carcinoma cell line ( Lewis lung cancer cells; 3LLSA ), which was originally established from the lung of a C57BL mouse bearing a tumor, was obtained from the Japanese Cancer Research Resources Bank. A murine melanoma cell line, B164A5, which also originated from a C57BL /6 mouse, 12, 13 was obtained from Riken Cell Bank ( Tsukuba, Japan ). 3LLSA was maintained in RPMI 1640 supplemented with 1% L -glutamine, 1% penicillin ± streptomycin, and 10% fetal calf serum ( RPMI /10% FCS ). B164A5 was maintained in high glucose ± Dulbecco's modified Eagle's medium (DMEM ) (Gibco BRL, Grand Island, NY ) containing 10% fetal calf serum (DMEM/ 10% FCS ).
cDNA and transfection
The expression vector containing murine CD40L cDNA encoding the entire coding region (BCMGS -neo-CD40L ) was a kind gift from Dr. Hideo Yagita (Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan ). BCMGS -neo-CD40L was transfected into 3LLSA cells as previously reported. 11 In brief, transfections were performed on 100 -mm plates using 10 g of plasmid DNA per plate by the lipofection method with Lipofectace reagent ( Gibco BRL, Gaithersburg, MD ), according to the manufacturer's instructions. After 24 hours of exposure, cells were washed three times with medium and cultured in 10 mL of normal medium. Twenty -four hours after medium exchange, cells were selected in medium containing 800 g/ mL G418 (Gibco, Grand Island, NY ). After 2 weeks of selection, G418 -resistant clones were selected randomly from the surviving colonies. Expression of the cell surface CD40L of these selected clones was analyzed by flow cytometry with an FITC -conjugated anti -murine CD40L mAb ( PharMingen, San Diego, CA ). The clone that showed the highest expression ( designated as 3LLSA -CD40L ) was selected and used in the following experiments. Murine IFN -cDNA subcloned into pBluescript KS + (pBluescript KS + mIFN -RDB No. 1482) was obtained from Riken Gene Bank (Tsukuba, Japan ). After EcoRI and NotI digestion, the IFN -cDNA was inserted into pcDNA3.1 Zeo expression vector (Invitrogen, San Diego, CA ), designated as pcDNA -IFN. 3LLSA cells were transfected with pcDNA -IFN using the lipofection method described above. Stable transfectants were obtained by selection in 600 g /mL Zeocin ( Invitrogen ). These selected clones were seeded into a 24 -well culture dish (10 5 per well ) and cultured for 24 hours, then supernatants from each well were collected to measure IFN -concentration using a murine IFN -enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN ) following the manufacturer's instructions ( data not shown ). The clone that produced the highest amount of IFN -was selected (designated as 3LLSA -IFN ) and used in the following experiments. 3LLSA -MOCK, which was established by transfecting the BCMGS -neo plasmid without a cDNA insert, was used in this study as a control. All these transfectants were cultured in RPMI 1640 /10% FCS.
Tumor growth
Parental 3LLSA or transfectants (3LLSA -CD40L, 3LLSA -IFN or 3LLSA -MOCK ) ( 
Tumor rechallenges
Either 3LLSA transfectant ( 3LLSA -CD40L, 3LLSA -IFN, or 30 Gy ± irradiated 3LLSA -MOCK ) or a mixture of the transfectants (3LLSA -CD40L + 3LLSA -IFN or 3LLSA -CD40L +30 Gy ± irradiated 3LLSA -MOCK ) was injected s.c. into the left shoulder of C57BL /6 mice. Four weeks later, these mice were rechallenged with 10 6 cells of the parental 3LLSA cells at the right shoulder. Tumor size at the right shoulder was measured weekly as described above.
Histological evaluation and immunohistochemistry
3LLSA -CD40L or 3LLSA -MOCK was inoculated into C57BL /6 mice. Seven days after inoculation, tumors were resected, fixed in 10% formalin, blocked in paraffin, sectioned at 2 m, and stained with hematoxylin and eosin. For immunohistochemical analysis, resected sections were Cancer Gene Therapy, Vol 8, No 6, 2001 embedded in OCT compound (Tissue-Tek, Sakura Finetechnical, Tokyo, Japan ), snap -frozen in liquid nitrogen, and mounted for cryostat sectioning. Five -micrometer -thick sections were air-dried and fixed with acetone and immunostained with biotinylated anti -mouse monoclonal antibody against CD4 and CD8 ( GK1.5 and 53 -6.7, respectively, Pharmingen ) and anti -asialo GM1 rabbit antibody ( Wako Pure Chemical Industries, Osaka, Japan ). For staining asialo GM1, the sections were blocked with diluted normal goat serum for 20 minutes, washed in PBS for 5 minutes, and then incubated with diluted anti -asialo GM1 rabbit antibody for 30 minutes. After washing twice, the sections were incubated with a biotinylated anti -rabbit IgG for 30 minutes in a humidified box at room temperature. For staining CD4 and CD8, the sections were incubated with PBS diluted monoclonal antibody for 1 hour in a humidified box at room temperature. After these procedures, all sections were washed in PBS for 5 minutes, incubated for 30 minutes in 0.3% H 2 O 2 in methanol, and then washed again in PBS for 5 minutes, following incubation with Vectastatin Elite ABC reagent (Vector Laboratories, Burlingame, CA ) for 30 minutes. After washing, the sections were incubated with AEC substrate reagent ( AEC Staining Kit, Sigma, St. Louis, MO ) for 10 minutes, followed by washing and counterstaining with 1% methyl green stain solution (Muto Pure Chemicals, Tokyo, Japan ).
CTL assays
Spleens were removed from C57BL / 6 mice that had been inoculated with the 3LLSA transfectant ( 3LLSA -CD40L, 3LLSA -IFN, or 30 Gy ± irradiated 3LLSA -MOCK ) or mixture of the transfectants (3LLSA -CD40L + 3LLSA -IFN or 3LLSA -CD40L +30 Gy ±irradiated 3LLSA -MOCK ). After preparing a single-cell suspension, 2Â10 6 spleen cells were cocultivated with 60 Gy ± irradiated wildtype 3LLSA cells (10 5 ) in 2 mL DMEM supplemented with 5% FCS, 50 M 2-mercaptoethanol ( Sigma ), 50 U / mL penicillin, 50 g /mL streptomycin, and 15 
Statistical analysis
Statistical analysis was performed using the Wilcoxon rank sum test and a P value below .05 was considered significant.
RESULTS
CD40L -transduced lung carcinoma cells are rejected in syngeneic mice by a CD40 ± CD40L ± dependent immune response A murine lung carcinoma cell line expressing CD40L ( 3LLSA -CD40L ) was established by transducing murine CD40L cDNA into parental 3LLSA cells as described in Materials and Methods. Inoculation of 3LLSA -CD40L cells into syngeneic C57BL / 6 mice resulted in complete rejection, though a small tumor mass was observed on day 7 ( Fig 1A ) . In contrast, 3LLSA -MOCK cells established by transducing the control empty vector grew as well as the parental 3LLSA cells (Fig 1A ) . The growth rates of these cell lines in vitro were not significantly different ( data not shown ). In CD40 -deficient mice, no difference in the growth rate was observed between 3LLSA -CD40L and 3LLSA -MOCK cells ( Fig 1B ) . IFN -±transduced 3LLSA ( 3LLSA -IFN ) cells, however, were rejected both in wild -type and CD40 -deficient mice (Fig 1A and B ) . These results indicate that the rejection of CD40L -transduced lung cancer cells in syngeneic wild -type mice was mediated by the CD40 ±CD40L interaction.
We analyzed histologic sections of tumors 7 days after 3LLSA -CD40L or 3LLSA -MOCK cells were inoculated into C57BL /6 mice. We observed the infiltration of inflammatory cells and some necrotic areas in 3LLSA -CD40L tumor tissue (Fig 2A ) , whereas 3LLSA -MOCK tumor tissue contained few inflammatory cells and no necrosis ( Fig 2B ) . Immunohistochemical study showed infiltration of CD4 + cells ( Fig 2C ) , CD8 + cells (Fig 2D ) and many NK cells (Fig 2E ) in the 3LLSA -CD40L tumor. These findings indicate that the transduction of the CD40L gene into cancer cells produced a local immune response against tumor cells.
Elicitation of local antitumor immunity by 3LLSA -CD40L
To investigate the effect of 3LLSA -CD40L inoculation on local antitumor response in vivo, we transplanted parental 3LLSA cells mixed with 3LLSA -CD40L cells into the C57BL /6 mice. As shown in Figure 3A , the inoculation of 3LLSA -CD40L cells inhibited the growth of parental 3LLSA cells, whereas this inhibitory effect was not observed when parental 3LLSA cells were inoculated with irradiated 3LLSA -MOCK cells (P < .02 ) ( Fig 3A ) . We next investigated whether co-inoculation of 3LLSA -IFN with 3LLSA -CD40L cells could augment the antitumor response against wild -type 3LLSA cells. When parental 3LLSA cells mixed with 3LLSA -CD40L and 3LLSA -IFN cells were inoculated into C57BL /6 mice, the growth of the tumor was significantly inhibited compared with the tumor growth when the parental cells were mixed with either 3LLSA -CD40L or 3LLSA -IFN cells ( P< .01 ) (Fig 3A ) . These results indicate that the transduction of CD40L gene into tumor cells could exert an antitumor immunity against parental tumor cells, and the inoculation of CD40L gene ± transduced tumor cells combined with IFN -gene ± transduced tumor cells could enhance the antitumor response.
To determine whether the antitumor immunity induced by 3LLSA -CD40L was 3LLSA tumor ± specific immunity or not, we inoculated B164A5 melanoma with the same number of 3LLSA -CD40L cells into C57BL / 6 mice. It was found that 3LLSA -CD40L significantly inhibited the growth of B164A5 (P < .05) and inoculation of B164A5 cells with 3LLSA -CD40L and 3LLSA -IFN cells resulted in almost complete rejection of the tumor (P < .002) ( Fig  3B ) . Considering that NK cells infiltrated the 3LLSA -CD40L tumor tissue (Fig 2E ) , we speculated that the enhancement of nonspecific antitumor immunity might be involved in part of the 3LLSA -CD40L ±induced local antitumor response.
Elicitation of tumor -specific and long -lasting antitumor immunity by 3LLSA -CD40L
It is important to determine whether transduction of the CD40L gene into lung cancer cells could induce systemic tumor-specific immunity. Therefore, we investigated whether inoculation of 3LLSA -CD40L could inhibit the parental 3LLSA growth at a distant site. Either 3LLSA -CD40L, 3LLSA -MOCK (30 Gy ±irradiated ) or 3LLSA -CD40L mixed with 3LLSA -IFN was implanted into the left shoulder of C57BL /6 mice, immediately followed by inoculation of parental 3LLSA into the right shoulder. Inoculation of 3LLSA -CD40L with or without 3LLSA -IFN tended to inhibit the growth of the parental tumor ( P= .074) (Fig 4A ) . However, 3LLSA -CD40L had no inhibitory effect on the growth of B164A5 melanoma cells when they were inoculated in the contralateral shoulder of the mouse ( Fig 4B ) .
We next investigated whether primary inoculation of 3LLSA -CD40L could elicit protective immunity, the socalled vaccine effect, against parental 3LLSA cells challenged after the rejection of primarily inoculated 3LLSA -CD40L. Four weeks after the primary inoculation of either 3LLSA -CD40L, 3LLSA -MOCK ( 30 Gy ± irradiated ), or 3LLSA -CD40L mixed with 3LLSA -IFN, C57BL / 6 mice were challenged with parental 3LLSA cells at a different site. As shown in Figure 5A , the inoculation of 3LLSA -CD40L resulted in the inhibited growth of parental 3LLSA cells challenged after the 3LLSA -CD40L rejection (P < .02 ). In addition, the implantation of 3LLSA -CD40L mixed with 3LLSA -IFN significantly enhanced the anti -3LLSA antitumor immunity (P < .05) ( Fig 5A ) . However, primary inoculation of 3LLSA -IFN without 3LLSA -CD40L did not inhibit the growth of parental 3LLSA cells challenged after the rejection of 3LLSA -IFN ( data not shown ). Furthermore, the growth of B164A5 melanoma cells was not affected after the rejection of 3LLSA -CD40L ( Fig 5B ) .
To confirm the induction of tumor-specific CTLs against 3LLSA after the inoculation of 3LLSA -CD40L cells, spleens were removed from mice injected with either 3LLSA -CD40L, irradiated 3LLSA -MOCK, or 3LLSA -IFN. The spleen cells were then subjected to secondary stimulation with parental 3LLSA cells to generate specific CTLs in vitro. Spleen cells from mice inoculated with 3LLSA -CD40L showed a greater induction of CTL activity than those from mice inoculated with 3LLSA -MOCK or 3LLSA -IFN (Fig 6 ) . Furthermore, the CTL activity in vitro was significantly enhanced when the 3LLSA -CD40L cells were inoculated with 3LLSA -IFN cells into C57BL /6 Figure 5 . Inoculation of 3LLSA -CD40L cells induce long -lasting tumor -specific immunity against later challenge of 3LLSA cells. C57BL / 6 mice were injected subcutaneously in their left shoulder with PBS ( control ), 3LLSA -CD40L ( 10 6 ), 30 Gy ± irradiated 3LLSA -MOCK ( 10 6 ), 3LLSA -IFN cells ( 10 6 ), or a mixture of 3LLSA -CD40L and 3LLSA -IFN ( 10 6 each ) at day 0. At day 30, mice were challenged on the right shoulder with 10 6 3LLSA cells ( A ), or 10 6 B164A5 cells ( B ). Tumor growth on the right shoulder was monitored weekly by measuring perpendicular tumor diameter with a caliper. The results are expressed as mean diameters ( in millimeters ) of tumors in four mice in each group. Error bars represent the standard deviation of the mean. The data are representative of at least two independent experiments. *P < .05; **P < .02. P values were calculated with the Wilcoxon rank sum test. Figure 6 . CTLs are generated in mice inoculated with 3LLSA -CD40L. C57BL / 6 mice were inoculated subcutaneously with 3LLSA -CD40L ( 10 6 ), 30 Gy ± irradiated 3LLSA -MOCK ( 10 6 ), 3LLSA -IFN cells ( 10 6 ), or a mixture of 3LLSA -CD40L and 3LLSA -IFN ( 10 6 each ). Four weeks later, spleens were removed from mice and splenocytes were cultured with irradiated 3LLSA cells. Subsequently, splenocytes were assessed for their cytotoxic activity against mice (Fig 6) . However, the CTLs did not kill the B164A5 melanoma target cells ( data not shown ). These results indicate that CD40L gene transduction into lung cancer cells could induce the tumor-specific cell -mediated immunity in vivo, and that the secretion of IFN -in tumor tissue enhanced the antitumor immunity induced by CD40 ± CD40L interaction.
DISCUSSION
Low immunogenic tumors, such as lung cancer, may be able to manipulate their environment and escape from the growth -restricting mechanisms of the host. 4 19 or RCAS1. 20 A recent report showed that tumor-associated macrophages suppress the expression of the CD3 chain of T-cell receptors. 21 It was also demonstrated that T cells, which infiltrate in an early stage of the tumor lesion, suppress the tumoricidal activity of NK cells. 22 To overcome these problems and elicit effective immunity against cancer, efficient activation of immunomodulatory cells involved in innate and adaptive immunity is required. 23 In this study, we demonstrated that transduction of the CD40L gene into lung cancer cells resulted in the establishment of antitumor immunity in vivo. CD40 ±CD40L interaction has been shown to play a central role in the induction of effective APC -T cell communication. 24 APCs including dendritic cells and macrophages can be activated via the CD40 ±CD40L interaction and produce IL -12, which induces the NK cell activation and Th1 responses, resulting in the generation of antitumor immunity. 25 Immunohistochemistry in this study revealed that NK cells and T cells infiltrated into the CD40L -transduced tumors (3LLSA -CD40L ) but not into the control tumor tissue (3LLSA -MOCK ), suggesting that 3LLSA -CD40L cells induce the activation of APCs surrounding the tumor. The activation of APCs through CD40 molecules enhances the surface expression of costimulatory molecules and adhesion molecules such as LFA -3, ICAM -1, CD80, or CD86 that are important for the efficient APC ± T cell interaction. 26 In addition, CD40 ligation on macrophages or monocytes enhances their TNF -production, and induces tumoricidal activity. 27 We have previously demonstrated that the 3LLSA -CD40L used in this study could activate murine alveolar macrophages and enhance their tumoricidal activity in vitro.
11 It is also known that CD40 ligation inhibits spontaneous or tumor-induced apoptosis of dendritic cells. 28 These facts apparently indicate that stimulation of APC through CD40 by CD40L -transduced tumor cells can efficiently enhance both innate and adaptive antitumor immunity.
Some malignant cells express CD40 on their surface, and the triggering via CD40 has been shown to affect the proliferation or apoptosis of the tumor. 29 In high -grade Bcell lymphoma cells and breast carcinoma cells, the signaling through CD40 shows the antiproliferative effect or increases apoptosis sensitivity. 29, 30 In contrast, CD40 triggering favors the growth of low-grade B -cell malignancies 29 or Kaposi's sarcoma. 31 Therefore, we examined the expression of CD40 on the cell surface of 3LLSA cells, and we also examined the direct suppression of wild -type tumor cell growth (3LLSA and B164A5 ) by CD40L gene ± transduced clones in vitro. FACS analysis revealed no CD40 expression on wild -type tumor cells with or without IFN -, nor could we observe any inhibition of wild -type tumor cell growth by stimulation with the irradiated CD40L gene ±transduced tumor cells ( data not shown ). Considering these findings, we concluded that the inhibitory effect for the growth of parental wild -type cells by CD40L transfectant in vivo was due to the activation of host immunity induced by CD40 ligation on APCs.
We showed that the simultaneous inoculation of CD40L transfected lung cancer cells (3LLSA -CD40L ) mixed with melanoma cells of B164A5 inhibited the subsequent cell growth of B164A5 in vivo. Two possible mechanisms may explain the``nonspecific'' inhibition of tumor cell growth at the site of tumor rejection. One is that macrophages or dendritic cells at the tumor site are activated through CD40 ± CD40L interaction, and they release cytokines and mediators such as TNF -or nitric oxide to kill tumor cells. 27 They also release IL-12 to recruit NK cells those are important for eliciting local antitumor response. 32 Our imunohistochemical study showing the enhanced infiltration of NK cells into 3LLSA -CD40L tumor may support this scenario. Another possible mechanism is that B164A5 cells inoculated with 3LLSA -CD40L were destroyed, phagocytosed, and processed by APCs activated via the CD40 ±CD40L interaction, and tumor-associated antigens of B164A5 cells were presented to T cells, resulting in the efficient generation of CTLs in a short time.
Previous reports have demonstrated the successful elicitation of in vivo protective immunity against tumors such as mastocytoma, leukemia, or neuroblastoma by using CD40L transfectant. 32, 33 We used lung cancer cell line 3LLSA, which is known to be a very low immunogenic tumor. 34 We did not observe the expression of H -2K (MHC class I ) on 3LLSA cells by FACS analysis ( data not shown ). It would be difficult to establish T cell ± mediated antitumor immunity against low immunogenic tumors such as 3LLSA cell tumors. However, our study suggests that the enhancement of CD40 ± CD40L signaling could generate tumorspecific CTLs and efficient systemic antitumor immunity even in low immunogenic tumors.
With regard to the treatment of lung cancer, we have reported that the alveolar macrophages did not express CD40 molecules on the cell surface, and IFN -induced a high expression of CD40 on the alveolar macrophages. Further, IFN -has been known to cooperate with CD40 engagement in modulating DC activity including high -level IL-12 production. 35 Therefore, we established the IFN -gene ± transduced clone, and transplanted it with the CD40L gene ± transduced lung cancer clone. Thus, the IFN -gene ± transduced clone provides IFN -locally at the site of tumor inoculation, resulting in the increase of the expression of CD40 molecules on the macrophage or APC, and their efficient activation via CD40L on the tumor cell surface.
Previous reports showed that the injection of recombinant CD40L with recombinant human fms ±like tyrosine kinase 3 ligand (Flt3L ) or cotransduction of GM -CSF and CD40L gene into tumor cells enhanced the antitumor immunity induced by CD40 ±CD40L interaction. 36, 37 In the present study, we showed that IFN -±transduced cells and CD40L -transduced cells cooperated efficiently in the generation of immune responses against parental tumor cells. We speculate that the in vivo priming with CD40L -and IFN -gene ± transduced lung cancer cells is a promising strategy for antitumor immunogene therapy for lung cancer.
